title: Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
abstract: OBJECTIVE
  To determine the effects of dehydroepiandrosterone (DHEA) supplementation on the pharmacokinetics of DHEA and its metabolites and the reproductive axis of healthy young men.
  
  
  METHODS
  A prospective, randomized, double-blind, placebo-controlled pharmacokinetic study.
  
  
  METHODS
  General Clinical Research Center and laboratories at the Keck School of Medicine of the University of Southern California, Los Angeles, California.
  
  
  METHODS
  Fourteen healthy men, ages 18-42 years.
  
  
  METHODS
  Daily oral administration of placebo (n = 5), 50 mg DHEA (n = 4), or 200 mg DHEA (n = 5) for 6 months. Blood samples were collected at frequent intervals on day 1 and at months 3 and 6 of treatment.
  
  
  METHODS
  Quantification of DHEA, DHEA sulfate (DHEAS), androstenedione, T, E(2), dihydrotestosterone (DHT), and 5alpha-androstane-3alpha-17beta-diol glucuronide (ADG). Physical examination, semen analysis, serum LH, FSH, prostate-specific antigen, and general chemistries were carried out.
  
  
  RESULTS
  Baseline DHEA, DHEAS, and ADG levels increased significantly from day 1 to months 3 and 6 in the DHEA treatment groups but not in the placebo group. No significant changes were observed in pharmacokinetic values. Clinical parameters were not affected.
  
  
  CONCLUSIONS
  DHEA, DHEAS, and ADG increased significantly during 6 months of daily DHEA supplementation. Although the pharmacokinetics of DHEA and its metabolites are not altered, sustained baseline elevation of ADG, a distal DHT metabolite, raises concerns about the potential negative impact of DHEA supplementation on the prostate gland.
authors.affiliation: Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Acacio
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: Patrick
authors.initials: P
authors.lastname: Mullin
authors.forename: Payam
authors.initials: P
authors.lastname: Saadat
authors.forename: Neda
authors.initials: N
authors.lastname: Jafarian
authors.forename: Rebecca Z
authors.initials: RZ
authors.lastname: Sokol
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015113:Androstane-3,17-diol / Q000031:analogs & derivatives* / Q000097:blood; D003687:Dehydroepiandrosterone / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D013196:Dihydrotestosterone / Q000097:blood; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D012016:Reference Values
chemical_list: D013196:Dihydrotestosterone; D015113:Androstane-3,17-diol; C028895:androstane-3,17-diol glucuronide; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate